Combination therapy for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of four drugs—bevacizumab, sintilimab, cetuximab, and irinotecan—in people whose colorectal cancer has spread and hasn't responded to previous treatments. The goal is to see if this new mix can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your colorectal cancer has spread to other parts of the body and cannot be removed with surgery.
- Your tumor is RAS wild-type (a specific genetic feature) and is MSS (microsatellite stable).
- You have tried at least two prior standard treatments that included fluoropyrimidine, irinotecan, and bevacizumab, but they stopped working.
- You are in generally good health, able to be up and about at least half the day (ECOG score 2 or less).
- Your blood counts, kidney function, liver function, and clotting tests are within acceptable ranges.
- You have not been treated with a PD-1 antibody before, and you do not have active autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
This study tests a new combination of drugs (Envafolimab, Cetuxima-β, and mFOLFOX6) for people with a specific type of advanced colorectal cancer that has not been treated yet. It aims to see if this combination is safe and more effective than standard treatments.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial combines a special type of radiation, immunotherapy, a targeted blood-vessel drug, and a chemotherapy pill for patients whose colorectal cancer has continued to grow after two prior treatments. The hope is that this combination can shrink tumors or slow down the cancer better than current options.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial is testing a new combination of three drugs (cetuximab, envolimab, and a chemo called mFOLFOX6) for people with advanced colorectal cancer that has not been treated yet. The goal is to see if this combination is safe and works better than standard treatments.
Hear when a new Colorectal Neoplasms Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.